Using the NGS technique applied to RNA, it is possible to analyze the transcriptome, or the set of RNA molecules in a cell, and determine when and where each gene is activated or deactivated in an organism's cells and tissues. In addition to the analysis of gene expression changes, RNAseq can be used to identify alternative splicing events, gene fusions and expression isoforms, to analyze unknown transcripts and for RNA editing, as well as for the analysis of noncoding RNAs.

The NGS technique applied to the DNA of any organism makes it possible to analyze by sequencing very large regions of the genome and gene pools. This tool offers several advantages such as:
- Scalability: sequencing large regions of DNA in parallel, with productivity advantages over Sanger sequencing;
- High resolution: it is possible to analyze base-by-base a gene, the exome or the entire genome;
- Provides quantitative measurements based on signal strength;
- Detects all types of genomic DNA alterations, including single nucleotide variations, insertions and deletions, copy number changes, and chromosomal aberrations;
- High productivity and flexibility: multiple samples can be analyzed simultaneously.

Epigenomics is the study of DNA organization at the genomic level, which is useful for assessing gene regulation at the transcriptional level, to identify protein binding sites to DNA or hypo- and hyper-methylated regions within the genome. Using methylation assays, for example, it is possible to obtain quantitative data on the methylation status at the level of CpG sites and thus to be able to understand, with good resolution, epigenetic changes.

yourSIAL Comprehensive Oncology Panel is a service to obtain a comprehensive genomic profile of tumor samples. It is possible to use this panel to identify all relevant DNA and RNA variants implicated in various types of solid tumors and to evaluate key immunoncology biomarkers, such as: microsatellite instability (MSI) and tumor mutational burden (TMB), a valuable tool to identify patients who can respond better to immunotherapy.
The service includes a bioinformatics analysis, which is the release of a report of all identified genetic variants, along with a TMB value.